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Abstract
A properly functioning adaptive immune system signifies the best fea-
tures of life. It is diverse beyond compare, tolerant without fail, and
capable of behaving appropriately with a myriad of infections and other
challenges. Dendritic cells are required to explain how this remarkable
system is energized and directed. I frame this article in terms of the ma-
jor decisions that my colleagues and I have made in dendritic cell science
and some of the guiding themes at the time the decisions were made. As
a result of progress worldwide, there is now evidence of a central role
for dendritic cells in initiating antigen-specific immunity and tolerance.
The in vivo distribution and development of a previously unrecognized
white cell lineage is better understood, as is the importance of den-
dritic cell maturation to link innate and adaptive immunity in response
to many stimuli. Our current focus is on antigen uptake receptors on
dendritic cells. These receptors enable experiments involving selective
targeting of antigens in situ and new approaches to vaccine design in
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DECIDING TO STUDY
IMMUNOLOGY
As explained elsewhere (1, 2), I had the good
fortune to grow up in Sherbrooke, Quebec, at-
tend McGill University in Montreal, and then
study medicine at Harvard Medical School and
Massachusetts General Hospital in Boston. All
along, my teachers made it fun to learn, per-
haps so much so that my decision to focus on
immunology did not emerge until the end of
my education in medicine. Then I became fas-
cinated with clonal selection theory by read-
ing Clonal Selection Theory of Acquired Immunity
(1959) by MacFarlane Burnet (3). The theory
tried to explain one of the hallmarks of the im-
mune system: its unique diversity and ability
to recognize determinants or antigens from a
spectrum of infections, tumors, transplants, self
tissues, and allergens. Burnet envisaged an ele-
gant repertoire of clones, each with an antibody
receptor specific for one antigen; immunization
required an initial selection step by the antigen
binding to its receptor. One of the amazing tri-
umphs of immunology during my subsequent
career was to see Burnet’s repertoire unraveled
through discoveries of how adaptive T and B
cells are formed, each expressing a single recep-
tor and together an unparalleled diverse library
of specificities.
During medical training in the late 1960s,
I attended a late afternoon set of seminars in
modern immunology organized by Kurt Bloch
at Massachusetts General Hospital. One of
the lectures described that macrophages were
accessories needed to initiate immunity. We
were taught that when a macrophage takes
up an antigen, an immunogenic RNA-antigen
complex is formed, and this instructed immune
cells to start making a specific antibody (4–6).
This was my first exposure to the idea that
clonal selection is not straightforward to
initiate; somehow antigen has to interact
with RNA from a macrophage. The scenario
seemed hard to believe given what was already
known about subcellular compartments and
their membrane barriers. Nevertheless, the
role of accessory cells in immunity seemed to
be a critical mystery to unravel.
During this same period of training in
medicine, a curious episode of fate involved
a so-called throwaway journal that medical
students received gratis in their hospital
mailboxes. An issue arrived that caught my
attention because it described the new field of
cell-mediated immunity and how important it
could be for medicine. The throwaway article
on cell-mediated immunity kept citing a series
of early reviews for the new field in the British
Medical Bulletin of 1965.
When I turned to that issue, Peter Medawar,
the father of transplantation, wrote, “We are
still generally ignorant of how a homograft re-
action starts” (7, p. 98). And James Gowans,
who discovered that lymphocytes are the medi-
ators of immunity, wrote, “Very little is known
about the way in which antigens from vascu-
larized grafts reach the lymphoid cells of the
host” (8, p. 107). How could there be uncer-
tainty about the initiation of the most power-
ful immune response in the body, when all that
seemed necessary was for the foreign antigens
on transplants to select clones with receptors
specific to these determinants?
Deciding how to approach this problem was
something I struggled with for two years be-
fore beginning my postdoctoral experiments.
In contrast, it was not a struggle to decide
that I needed to work with Zanvil Cohn and
James Hirsch at The Rockefeller University.
They were leaders in the modern cell biology
of phagocytes, and these were the cells deemed
to be critical accessories to initiate immunity.
Fortunately, I gained a position in their Lab-
oratory of Cellular Physiology and Immunol-
ogy. When I began my postdoctoral research,
I did not have a hypothesis that a new cell type
must exist to understand how immunity begins.
Rather, I had a commitment to what I thought
was a major problem: How does the body de-
cide to make an immune response, especially
a cell-mediated one, when antigen enters the
body? Or to put it another way, how is Burnet’s
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The decision to emphasize problems that
appear central to medicine is something I will
never abandon, and, of course, I am not alone in
this. The relevance of immunology to so many
disease states (Figure 1) is not something one
just mentions in a search for grant funds. In-
stead, it is a thrilling driving force for choosing
which experiments and experimental systems to
pursue. I dislike the much-used distinction be-
tween basic and clinical immunology. Research
on diseases and in patients are both basic. For
example, the simultaneous discovery of TNF
by Anthony Cerami at Rockefeller and Lloyd
Old at Memorial Sloan Kettering Cancer
Center was fundamental, but was it not equally
basic for Marc Feldmann and Ravinder Maini
in London to make the shocking discovery
that anti-TNF antibodies were able to block
severe inflammatory diseases in people with
rheumatoid arthritis? The word “translational”
can be helpful in one sense, by indicating to our
community of supporters that we are studying
disease and often patients. But too often the
term implies that medical progress comes from
a simple translation or implementation of basic
studies and that research with patients and
pathogens is not part of the discovery equation.
This is untrue. Research attempts to uncover




The route to identifying dendritic cells was not
direct (1, 2). The key decision was to examine
the spleen and move away from the peritoneal
cavity, which remains a focus of macrophage re-
search. Others had shown that spleen cell sus-
pensions are special because they can be used
to study the initiation of antibody responses in
culture (9). But why? Once we looked at the
spleen cells, we quickly observed novel cells,
dendritic cells as we called them, and began to
try to understand them. They did not look like
macrophages, and this was soon reinforced with













Medical conditions to which the immune system contributes
Figure 1
The immune system contributes to various medical conditions, either to
protect against disease, including with vaccination and immune therapies, or to
contribute to pathology and symptoms. At the bottom of the figure are areas
being studied more recently for their immune involvements: atherosclerosis
and bone disease. All these conditions either are becoming more frequent or, in
the case of a disease such as cancer, are decreasing very little. Also, new
infections always evolve, most notably AIDS, which was not known when I
began my career.
It was invaluable that Zanvil Cohn and all
the scientists in the lab had a rich experience
with macrophage biology. This provided a
huge boost to work out that dendritic cells are
entirely different from macrophages, even if
others at the time did not agree. Also critical
was that The Rockefeller University was the
birthplace of many discoveries in modern
cell biology and subcellular structure. David
Sabatini’s glutaraldehyde fixation method used
for electron microscopy and cytochemistry
preserved dendritic cells in their distinctive
form, which was similar to what we observed in
the living state by phase contrast microscopy.
Other major breakthroughs in cell biology were
the identification of lysosomes by Christian de
Duve (12) and the elegant mechanisms from
Cohn, Hirsch, and colleagues (13) on uptake
and delivery of particles to digestive lysosomes
in macrophages. It was quickly shown that
dendritic cells have few standard lysosomes by
morphology or acid phosphatase staining, and
phagocytosis was tough to demonstrate. These
cells were unusual.














































































IY30CH01-Steinman ARI 17 February 2012 10:54
By 1978, eight years after beginning re-
search at Rockefeller, I still had the impor-
tant problem of elucidating how immunity is
initiated. I was aware of a cell type that did
not look like or behave like any monocyte or
macrophage that had been encountered. I en-
joyed the unshakable patience and wisdom of
Zanvil Cohn. I could identify the distinct den-
dritic cell by its unusual cell shape and or-
ganelles so that I could eventually purify it.
Then I observed its high expression of major
histocompatibility complex (MHC) molecules
with effective antibodies that had just become
available, and I began to assay function (14).
I wonder whether I could succeed today
in obtaining my first grant, AI13013, now
in its 36th year, to pursue these dendritic
cells. Many funding sources provide research
support almost exclusively on the basis of the
specifics and feasibility of what one plans to
do. Research funding should instead prioritize
individuals who have done special groundwork
and want to use their discoveries to pursue an
important problem. In other words, funding
should be determined by what the investigator
brings to the table from his or her past work
and the importance of the problem he or
she chooses to study. It is simply illogical
to award funds for a feasible and detailed
future approach, in which case the biological
unknown is likely doomed to be incremental.
In writing my first grant, even after spotting
unusual cells, I could not have hypothesized that
dendritic cells would prove to be unique ini-
tiators of immunity. In the early 1970s, there
were several possible roles for “accessory cells,”
one being the retention of intact antigen, par-
ticularly immune complexes on the cell sur-
face. This was observed in vivo on “dendritic
macrophages” (now called follicular dendritic
cells, FDCs) (15). I did manage to show with
Lei Chen that persistence in vivo is truly on the
cell surface of the FDC (16, 17). This meant that
FDCs are very different from macrophages, on
which I had failed previously to show retention
of intact antigen and immune complexes in spite
of large amounts of endocytosis (18). But I was
also unable to show binding of intact antigen
or antibody complexes to the newly recognized
dendritic cells.
In fact, it took almost five years of ef-
fort, largely on cultures that allowed the mas-
sive expansion of antibody-forming cells (19),
to decide to study the in vitro counterpart
of Medawar’s transplant rejection, the mixed
leukocyte reaction (MLR) (20). The dendritic
cells proved to be the principal and surpris-
ingly potent stimulator cells, whereas MHC-
bearing macrophages and B cells were weak.
It took another five years for Robert Lech-
ler and Richard Batchelor in London to re-
port that dendritic cells are unique inducers of
transplant rejection in vivo (21). During these
slow early years, I benefited from essential sup-
port from the Leukemia Society of America, the
American Heart Association, and the Irma T.
Hirschl Fund, and again, I had the unique en-
couragement of Zanvil Cohn. Then in the late
1970s, after the initial years of struggle, the
pace changed markedly when I was joined by
PhD students Michel Nussenzweig and Wes
van Voorhis, and by Kayo Inaba, fresh from her
PhD in Kyoto.
DISSECTING THE AFFERENT
AND EFFERENT LIMBS OF
CELL-MEDIATED IMMUNITY
As mentioned, the first functional assays we
used to identify the immune-initiating function
of dendritic cells did not involve the addition of
antigens that needed to be processed. Instead,
we used responses in the MLR, a reaction in
which T cells largely recognize endogenous
peptides complexed to the foreign MHC. A
similar situation took place in the laboratories
of William Bowers and Jon Austyn, who
observed the potent accessory function of
dendritic cells relative to other cell types using
a polyclonal mitogenesis assay in which T
cells were treated with sodium periodate (22,
23). But then we began to move forward with
immunity to specific added antigens (still the
focus of the lab), for which the reactive T cell
clones are rare. However, we were not initially
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peptide MHC products. This was unraveled
only later from the work of many other
investigators, particularly Emil Unanue, Alain
Townsend, Jack Strominger, Don Wiley, and
Pam Bjorkman.
Nonetheless, dendritic cells were quickly
shown to effectively present complex antigens
to T cells. Nussenzweig demonstrated that
dendritic cells present exogenous antigen to
T cells in an MHC-restricted fashion and
that they induce specific cytolytic T cell re-
sponses (24). He co-cultured the dendritic cells
with T cells, irradiated trinitrophenyl (TNP)-
modified thymocytes, and found that the T cells
developed MHC-restricted cytolytic activity.
Although not appreciated at the time, this was
also the first demonstration of “cross-priming”
by dendritic cells. Wes van Voorhis showed
that human blood contains dendritic cells simi-
lar to the ones we had found in mice (25), and he
studied presentation of Candida to proliferating
T cells. Inaba, as she had begun to do during her
PhD (26), analyzed a system employing sheep
red blood cells, a classical antigen at the time to
study helper T cell function in antibody forma-
tion (27). In all these systems, small numbers of
dendritic cells elicited a T cell response, while
much larger numbers of other cell types were
inactive. Early reviews emphasized the features
of this newly uncovered lineage of white cells
(28, 29).
These findings made us want to understand
what the MHC is doing when expressed on
other cell types. Inaba and I decided to study
distinct cell clusters—5–10 cells in width—
which we routinely observed in our cultures
when dendritic cells were initiating immunity.
The clusters contained most of the dendritic
cells in the culture, and these were bound to
lymphocytes. The clusters proved to be the
sites for the onset of lymphocyte prolifera-
tion or “blastogenesis,” but then the responding
“blasts” moved away from the cluster. When
purified, the primed T cells showed responses
to other cell types presenting antigen. For ex-
ample, Inaba found that B cells fail to initiate
T cell immunity to a soluble protein but could
interact vigorously with the antigen-specific
and MHC-restricted T blasts that are first in-
duced by dendritic cells (30, 31). James Young,
Sumi Koide, and Jon Austyn extended this two-
step mechanism to other assays for successful
T cell responses (23, 32, 33).
The experiments led by Inaba were long
lasting in two respects, as summarized in later
reviews on the importance of dendritic cells
in immunogenicity (34, 35). First, dendritic
cells are not simply antigen-presenting cells
but, in addition, are specialized accessories for
initiating immunity. All cells that express MHC
molecules can use these to present antigen—
but primarily to activated T cells. Second, we
proposed an in vivo counterpart for the findings
with cell clusters, based on several prior sets of
observations: that immune responses begin in
lymphoid organs; that T blasts pour into the
thoracic duct lymph from lymphoid tissues sev-
eral days after the onset of an immune response;
and that the main place that dendritic cells can
be found is in T cell zones (36). Therefore, we
envisaged that dendritic cells would initiate the
“afferent limb” of immunity by presenting anti-
gen in the T cell areas of lymphoid tissues in
vivo, and later the activated T cells would leave
via the lymph, enter the thoracic duct and then
the blood, and finally reach the inflamed tissues
to bring about the efferent or effector limb of
immunity.
These early assays, as well as the antigens
that dominated research in immunology at the
time, may seem remote to younger readers, but
the underlying themes live on. In particular, the
availability of dendritic cells makes it possible
to initiate immunity with intact specific anti-
gens. It was not necessary to focus on prepro-
cessed peptides and various mitogens. With-
out knowing about antigen processing, we were
finding that dendritic cells were carrying out
the two series of events needed for T cells to
start their protective and pathogenic functions,
i.e., dendritic cells allowed T cells to recognize
antigen (later peptide MHC complexes) and to
respond to it (later accessory or costimulatory
functions).
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Table 1 International symposia on dendritic cells in fundamental and clinical immunology
City Date Organizers
I Yamagata City, Japan June 1990 Y. Imai
II Amsterdam, Holland June 1992 E.C.M. Hoefsmit, P. Nieuwenhuis, E.W.A.
Kamperdijk, A.C. Dijkstra
III Annecy, France October 1994 J. Banchereau, D. Schmitt, L. Valette
IV Venice, Italy October 1996 P. Riccardi-Castagnoli, G. Girolomoni,
A. Lanzavecchia
V Pittsburgh, USA September 1998 M. Lotze, J. Banchereau, R. Steinman
VI Port Douglas, Australia May 2000 K. Shortman, D. Hart, P. Holt, P. Wood
VII Bamberg, Germany September 2002 G. Schuler, A. Steinkasserer, G. Stingl
VIII Bruges, Belgium October 2004 M. Moser, K. Thielemans, T. Boon
IX Edinburgh, Scotland September 2006 G. MacPherson, J. Liversidge, J. Austyn
X Kobe, Japan October 2008 M. Furue, K. Inaba, S. Koyasu,
K. Matsushima
XI Lugano, Switzerland September 2010 A. Lanzavecchia, M.G. Manz, F. Sallusto
XII Daegu, South Korea October 2012 H-Y. Kim, Y-S. Bae, C-K. Lee
A relatively small but international commu-
nity was actively contributing to dendritic cell
research in fundamental and clinical immunol-
ogy in the 1980s. Sizeable international biennial
meetings dedicated to this theme began in 1990
(Table 1) and in alternating years at Keystone
Symposia in the United States (Table 2). The
organizers of these conferences include many
of the leaders in dendritic cell biology over the
years. Nevertheless, before the early 1990s,
dendritic cells were not really on the main
stage of immunology. This was largely because
immunology was profitably absorbed with the
crucial understanding of MHC restriction,
antigen processing and presentation, and the
T cell receptor. These events could be studied,
at least initially, with already immunized
T cells and T cell lines, clones, and hybrido-
mas. Isolating dendritic cells for this kind
of antigen presentation research was not
critical initially. But today, direct attention to
dendritic cells is valuable for many mechanistic
studies, e.g., antigen uptake and presentation;
the links between innate and adaptive immu-
nity; T cell differentiation; dynamics of the
immune system in situ; stimulation of other
lymphocytes, especially NK cells; and clinical
immunology.
TRACING THE DEVELOPMENT




Understanding development is essential to
defining a cell lineage. Our first experiments
in this sphere came through a decision by
Gerold Schuler from Innsbruck to join our lab
to determine how epidermal Langerhans cells
relate to spleen dendritic cells. He discovered
what we termed dendritic cell maturation
(37). We prefer the term “maturation” to
“activation” because the latter typically refers
to an on-off event or restricted series of events,
whereas what we were observing was the
large-scale differentiation of a cell lineage,
which is called maturation when, for example,
myelocytes become neutrophils or normoblasts
become red cells. Dendritic cell maturation is
the critical link between innate and adaptive
T cell–dependent immunity.
The concept is that dendritic cells respond
quickly to environmental changes and dif-
ferentiate extensively to become mature or
immunogenic accessory cells. Microbes are not
the only sources of these stimuli. There are
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Table 2 Keystone Symposia on dendritic cells
Year and place Symposium title Organizers
1995
Taos, NM
Dendritic Cells: Antigen Presenting Cells of T
and B Lymphocytes
Jacques Banchereau and Ralph Steinman
1998
Santa Fe, NM
Cellular and Molecular Biology of Dendritic
Cells




Dendritic Cells: Interfaces with
Immunobiology and Medicine




Dendritic Cells: Interfaces with
Immunobiology and Medicine
Ralph M. Steinman, Anne O’Garra, and Jacques
Banchereau




Dendritic Cells at the Center of Innate and
Adaptive Immunity: Eradication of Pathogens
and Cancer and Control of Immunopathology
Anne O’Garra, Jacques Banchereau, and Alan Sher
2007
Keystone, CO
Intracellular and Intercellular Signaling in
Dendritic Cell Function
Muriel Moser, Caetano Reis e Sousa, and
Yong-Jun Liu
Joint with Imaging Immune Responses Ronald N. Germain and Ellen A. Robey
2009
Banff, Alberta
Dendritic Cells Giorgio Trinchieri, Gwendalyn J. Randolph, and
Sebastian Amigorena
Joint with Pattern Recognition Molecules and Immune
Sensors of Pathogens




Dendritic Cells and the Initiation of Adaptive
Immunity
Ira Mellman, Michel C. Nussenzweig, Virginia
Pascual, and Federica Sallusto
Joint with Cancer Control by Tumor Suppressors and
Immune Effectors (Tumor Immunology)
Laurence Zitvogel, Anna Karolina Palucka, and
Mark J. Smyth
2013
Venue to be determined
Understanding Dendritic Cell Biology to
Improve Human Disease
Miriam Merad and Bart Lambrecht
powerful settings for cell-mediated immunity,
graft rejection and contact hypersensitivity,
which take place in ostensibly nonmicrobial
settings. Maturation occurs whenever epider-
mal dendritic cells, and spleen dendritic cells in
later experiments, are placed in culture. Maggi
Pack found that one critical factor for the mat-
uration of Langerhans cells was GM-CSF (38).
The surprise behind all this was that we had
previously assumed that dendritic cells in vivo
are fully ready to initiate immunity because of
their high levels of MHC class II (MHCII)
molecules in spleen and in skin. But when Ira
Mellman and his colleagues at Yale decided
to bring expertise in cell biology to dendritic
cells, they found that the MHCII products are
largely sequestered within the endocytic system
(39). There, the MHCII molecules wait for a
maturation stimulus to trigger endosomal acid-
ification (40) and thereby the catabolism of pro-
tein antigens and the MHCII-associated invari-
ant chain. These two key steps are required to
allow peptide-MHCII complexes to form inside
the endocytic system, followed by their subse-
quent display at the cell surface (41, 42). More
research is needed, but the endocytic system—
its regulation and composition—is turning out
to be one of the hallmark differences between
dendritic cells and macrophages.
Niki Romani likewise made surprising find-
ings with dendritic cells from the skin. The
immature cells capture antigens while the ma-
ture ones are ineffective; in contrast, the mature
cells are very strong immune stimulators for T
cells specific for antigens captured earlier (43).
This finding was one of the early indications in
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immunology that the initiation of immunity re-
quires two large components: (a) antigen cap-
ture and presentation and (b) the expression of
many accessory functions. I still prefer the term
“accessory” because it encompasses the many
specializations of dendritic cells for initiating
immunity. These go beyond formal costimula-
tion of the T cell receptor.
Many investigators use the word maturation
when only “phenotypic maturation” has been
documented. Typically, this means increased
expression of CD40/80/86 and more recently
PD-L1/CD274 and PD-L2/CD273. Pheno-
typic maturation is not identical to functional
maturation or immunogenicity. Many changes
that comprise the maturation phenotype are
actually secondary to inflammatory cytokines,
which Shin-ichiro Fujii and Kanako Shimizu
found when they studied functional maturation
mediated by natural killer T (NKT) cells in vivo
(44, 45). A big gap currently is the incomplete
molecular understanding of functional matura-
tion, i.e., what events take place directly when
a dendritic cell encounters a microbial product,
an alarmin, an innate NK cell, or a CD40 ligand
on a mast cell and platelet. Cytokine production
by dendritic cells is a critical initial step in mat-
uration, but many cells make cytokines. One
needs in the future to identify the constellation
of changes in dendritic cells, not only cytokines,
that leads to the initiation of the appropriate
immune response, and sometimes to inappro-
priate ones. These include allergy as reviewed
by Bart Lambrecht and Hamida Hammad from
Ghent (46) and systemic lupus erythematosus
as reviewed by Lars Ronnblom and Virginia
Pascual from Uppsala and Dallas (47).
The other area of dendritic cell develop-
ment that we decided to study in the early days
of the field was the identification of progeni-
tors. With Gerold Schuler and Kayo Inaba, we
began this demanding project in mice (48–50),
while Jacques Banchereau, Christophe Caux,
and colleagues in Dardilly were doing similar
experiments with human CD34+ progenitors
(51). The first concept was that dendritic cells
develop from a common myeloid progenitor
that gives rise to granulocytes, macrophages,
and dendritic cells. In our cultures, the different
myeloid progeny were separated on the basis
of plastic adherence and clustering properties,
allowing us to show the typical morphology and
phenotypic features of dendritic cells, includ-
ing the later finding that the immature forms
are capable of modest but clear phagocytic
activity (52). Soon thereafter, using monocytes
rather than marrow progenitors, Federica
Sallusto and Antonio Lanzavecchia (53) and
Romani, Schuler, and colleagues (54) de-
termined that a combination of GM-CSF
and IL-4 (or IL-13) can induce the initial
differentiation of human monocytes to acquire
phenotypic features associated with dendritic
cells and that development is completed
following application of a maturation stimulus
(55). Consistent with the idea that maturation
is the essential link between innate and adaptive
immunity, Sallusto and Lanzavecchia studied
lipopolysaccharide (LPS) as a maturation
stimulus (55), before the identification of
responsible Toll-like receptors (TLRs).
These methods to develop large numbers
of monocyte-derived dendritic cells in vitro
changed the field because investigators could
more easily study their immunizing proper-
ties. This included Inaba’s use of antigen-
loaded dendritic cells to immunize healthy
mice (52, 56) and later Madhav Dhodapkar’s
and Nina Bhardwaj’s research showing that
antigen-loaded dendritic cells could immunize
humans (57, 58). But still, something impor-
tant was missing. Despite the use of GM-CSF
in these systems for dendritic cell development,
Ken Shortman in Melbourne showed that mice
deficient in GM-CSF and GM-CSF receptor
can have quite normal numbers of dendritic
cells in the steady state (59).
Several investigators have uncovered the
missing link in vivo, another hematopoietin,
flt-3L. Eugene Maraskovsky, with the former
Immunex Corporation in Seattle, found that
repeated injection of flt-3L into mice (60)
and humans (61) leads to a dramatic 10- to
15-fold expansion of dendritic cells. The
laboratories of Li Wu in Melbourne (62) and
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that the dendritic cell progenitor in marrow is
responsive to flt-3L. Waskow and Liu, working
in the Nussenzweig laboratory at Rockefeller,
defined the progenitors of dendritic cells in
the bone marrow (64–66). They discovered
intermediates in the myeloid differentiation
pathway that define the split between dendritic
cells and monocytes during development. In
addition, they showed that under steady-state
conditions, dendritic cell–committed precur-
sors emigrate from the bone marrow and seed
lymphoid and nonlymphoid tissues, where
they divide under the control of flt-3L to fill
the dendritic cell compartment. Thus, in the
steady state, a critical part of the definition
of the dendritic cell lineage is its dependence
on flt-3L. An exception is the epidermal
Langerhans cell, which as reviewed by Miriam
Merad and colleagues has a separate origin (67).
Frederic Geissmann, now in London,
defined a common bone marrow progenitor
that gives rise to both monocytes and dendritic
cells. The split between the two pathways
was defined by Liu and Nussenzweig (64):
Monocytes remain dependent upon M-CSF,
and the dendritic cells remain dependent on
flt-3L. The dendritic cell progenitor moves
into lymphoid and nonlymphoid organs (64),
the latest example being Kang Liu’s research
with the meninges of the brain (68). Niroshana
Anandasabapathy is leading a new clinical
study with Celldex Therapeutics to pursue
flt-3L in people. We want to confirm that
this hematopoietin can expand many different
types of dendritic cells roughly 10-fold in
people. After following U.S. Food and Drug
Administration guidelines to reevaluate in
detail new lots of flt-3L clinical product for
safety and efficacy, the product can then be
used, for example, to test whether dendritic
cell expansion can enhance immune control in
vaccination and in autoimmunity.
But there may be a way for monocytes
to become dendritic cells in vivo in parallel
with the much-used human monocyte tissue
culture system also mentioned above. Cheolho
Cheong, Ines Matos, and Chae Gyu Park found
a surprising pathway for this differentiation,
surprising because it had been overlooked
for so long. The monocyte–to–dendritic cell
conversion occurs when mice are given a high
dose of LPS or gram-negative bacteria (69).
Rapidly, within 6 h, blood monocytes move
into peripheral lymph nodes and differentiate
via TLR4, Trif, and CD14 into typical func-
tional dendritic cells. Importantly, the addition
of LPS to mouse or human monocytes does
not directly convert monocytes to dendritic
cells; rather, additional, still unknown events
must occur in mice that allow this transition
to take place. Also uncertain are the functions
of monocyte-derived, flt-3L-independent
cells in many tissues, particularly lung and
intestinal lamina propria. These are often
called dendritic cells, but more study of their
antigen-presenting functions is required,
as Saurabh Mehandru is now undertaking.
Curiously, the first nonlymphoid tissue in
which functional flt-3L-dependent and M-
CSF-dependent dendritic cells have been stud-
ied side by side is probably the most demanding
one, the mouse aorta, as shown recently by
Jaehoon Choi and Cheolho Cheong (70).
Monocyte-derived dendritic cells in vivo
share a property with their cultured counter-
parts, which is the capacity to present nonrepli-
cating proteins on MHC class I (69). This is
termed “cross-presentation” and is a hallmark
of one subset of dendritic cells in lymphoid tis-
sues, the CD8+ subset. This allows monocyte-
derived dendritic cells to cross-present antigens
to CD8+ T cells from immune complexes, as
shown by Sebastian Amigorena in Paris (71),
and from dying infected cells, as shown by
Matthew Albert and Nina Bhardwaj in New
York (72).
The advances in knowledge of dendritic
cell development that are coming from many
laboratories now make it possible to better
understand and work with the lineage. The
future will yield even more clarity when
the driving forces for the gene-expression
programs of dendritic cells are unraveled at the
levels of transcription factors and microRNAs.
Several relevant transcription factors have been
identified for dendritic cell development, e.g.,
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the E2-2 zinc finger protein is selective for a
particular pathway of dendritic cell develop-
ment, in this case plasmacytoid dendritic cells
(73). Likewise, the driving forces for dendritic
cell function must be defined after develop-
ment, i.e., to account for dendritic cell proper-
ties in the steady state and during maturation.
USING DEC-205 TO DIRECT
DENDRITIC CELLS IN SITU,
INCLUDING THE CONTROL
OF IMMUNE TOLERANCE
By the 1990s, the dendritic cell field was still
quite limited in terms of molecular tools. Early
on, Nussenzweig had used a panel of available
monoclonal antibodies to study the cell surface
of dendritic cells; the main positive finding was
the high expression of MHC products (74). The
expression of high levels of the CD11c integrin
was found some years later and shown to be
useful to enrich dendritic cells (75, 76). How-
ever, CD11c is not cell-type specific, as is the
case for the other leukocyte integrins, CD11a
and CD11b. The latter integrins were initially
thought to be cell specific and were termed lym-
phocyte function–associated antigen and Mac-
1, respectively. Others have commented on the
usefulness of high CD11c expression to identify
many dendritic cells, as well as clear CD11c ex-
pression on other cell types (77). Expression of
this integrin by itself should not be used to de-
fine the dendritic cell lineage, especially when
function and development are not brought to
bear on the analysis.
To gain more discrimination, we decided
to isolate the molecule recognized by a mono-
clonal antibody, NLDC-145, that Georg Kraal
in Amsterdam had found (78). The target
for the NLDC-145 antibody was intriguing
because it was mainly expressed on dendritic
cells in the T cell areas and on cortical thymic
epithelium and other epithelia (79). As shown
by William Swiggard during his PhD studies,
the NLDC-145 antigen turned out to be a
205-kD protein (80). Swiggard obtained some
distinctive peptide sequences, and Wanping
Jiang, a postdoctoral fellow in the Nussen-
zweig laboratory, cloned the cDNA (81). The
sequence predicted 10 external lectin domains,
hence the new name DEC-205, given that it
was a decalectin and was expressed on both
dendritic cells and epithelial cells.
We could not have foreseen what emerged
from the cloning. The molecule was a cousin
of the macrophage mannose receptor that
Siamon Gordon in Oxford had studied; this
receptor was later shown to be expressed on
macrophages and sinus lining endothelium in
vivo, but not in the T cell areas (82). Phil Stahl
in St. Louis had studied the mannose receptor
as an early example of receptor-mediated ad-
sorptive endocytosis. As predicted from the se-
quence homology, DEC-205 mediates adsorp-
tive uptake via coated pits into the endocytic
system and greatly enhances the efficiency of
antigen presentation (81, 83).
A human DEC-205 counterpart was quickly
identified (84). Since that time, a plethora
of uptake receptors, especially type II trans-
membrane proteins with a single external C-
type lectin domain, have been found on differ-
ent types of dendritic cells in situ. Curiously,
DEC-205 is the only one at this point that has
been visualized on many dendritic cells in the
T cell areas of human and mouse lymphoid tis-
sues (85). Gaelle Breton and Maggi Pack are
now searching for good reagents, and, together
with Paul and Klara Racz in Hamburg, we are
trying to overcome the lack of information on
the expression of various dendritic cell lectins
in humans and nonhuman primates in situ.
The natural ligands for DEC-205 are still
unknown, but we decided early on to use
antibodies as surrogate ligands. Nussenzweig
realized that the way to move forward was
to engineer the heavy chain of the anti-DEC
monoclonal antibody to express different anti-
gens. In this way, the consequences of targeting
antigens to dendritic cells could be studied in
vivo without having to isolate the dendritic
cells or generate them from precursors.
The first antigen that was engineered into
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lysozyme (HEL), which dominates the CD4+
T cell response of H-2k mice. The injected
antibody targeted to the dendritic cells in the
T cell area, as expected from the natural ex-
pression of the corresponding antigen, but the
consequence of antigen presentation provided
a major surprise, which was recorded with
HEL-specific transgenic T cells (86). Daniel
Hawiger and Nussenzweig showed that the T
cells first underwent clonal expansion, but then
the T cells disappeared and the animal became
specifically tolerant to HEL. Laura Bonifaz
made similar findings with ovalbumin-specific
CD8+ T cells (87), while Kristen Tarbell,
Xunrong Luo, and Sayuri Yamazaki used den-
dritic cells to expand and induce regulatory T
cells (Tregs) specific for a beta cell autoantigen
in culture (88, 89). Kang Liu targeted dying
cells to dendritic cells in vivo, and again the
consequence was deletion and tolerance or un-
responsiveness (90). Before these discoveries,
the thinking in the field had been that dendritic
cells in lymphoid tissues were already in a
mature immunogenic state, yet the new results
led to the opposite interpretation. Dendritic
cells in the steady state function in peripheral
tolerance.
Antigen targeting is enabling researchers
to probe the induction of antigen-specific
regulatory or suppressor T cells in the intact
animal. Harald von Boehmer in Boston (91),
Karsten Mahnke in Heidelberg (92), and
Sayuri Yamazaki in our lab (93) showed that
targeting of a foreign protein to dendritic cells
in vivo in the steady state allowed some Foxp3−
CD4+ T cells to become Foxp3+. To date,
however, most model systems in vivo have
not involved true self antigens or large-scale
induction of Foxp3+ Tregs. Juliana Idoyaga is
addressing these issues in ongoing experiments
with an autoantigen from myelin that drives
multiple sclerosis in mice. The concept that
dendritic cells can bring about peripheral
tolerance in vivo should lead to methods for
the antigen-specific silencing of immunity, as
would be desirable in allergy, autoimmunity,
transplantation, and perhaps atherosclerosis.
DISTINGUISHING DENDRITIC
CELL SUBSETS
Many different laboratories decided to look for
additional molecular markers to identify and
understand dendritic cells. A surprising result
was that in the steady state, the markers were
expressed by some but not all dendritic cells.
For example, Ken Shortman in Melbourne
found CD8 on a subset of classical dendritic
cells in mouse lymphoid organs (94); Yong-Jun
Liu in Dardilly with Banchereau found CD11c
and CD4 on myeloid and plasmacytoid sub-
sets, respectively, of human blood dendritic
cells (95); and Joern Schmitz at the Miltenyi
Corporation in Germany described blood
dendritic cell antigens, BDCA-1, -2, and -3,
which identify two types of myeloid dendritic
cells (BDCA-1 and -3) and plasmacytoid
dendritic cells (BDCA-2) (96). Curiously,
these molecules have not yet been adequately
represented in functional studies.
The opposite is the case for a plethora of
molecules that enhance antigen uptake and pre-
sentation, which also frequently mark subsets
of dendritic cells (Figure 2). This began with
DEC-205, discussed above, which is expressed
at high levels on one subset of dendritic cells in
mice. Diana Dudziak with Nussenzweig found
that another dendritic cell marker, identified
by the first 33D1 monoclonal to dendritic cells
(97), is also a lectin expressed by one type of
dendritic cell (98). Juliana Idoyaga pursued lan-
gerin as a dendritic cell subset marker that can
mediate uptake and presentation of antigens
(98, 99). Actually, receptors for innate immu-
nity, for both uptake (usually lectins) and sig-
naling (usually TLR), are often expressed more
on one dendritic cell subset than on another
(Figure 2).
One complex example uncovered by Inaba
in Kyoto is the preferential uptake of dying
cells by the CD8+ subset of dendritic cells
in vivo. This uptake is followed by efficient
cross-presentation to CD8+ T cells. Not only
are the dying infected cells processed onto
MHC class I, as in the initial discovery (72),
but the endogenous antigens in transformed































































































Different types of dendritic cells in mice and markers used to identify them. These markers are often lectins for antigen uptake,
although treml4 identified by Hiroaki Hemmi (134) is an Ig superfamily member discovered in our efforts to find receptors that bind
necrotic cells. In addition to innate receptors for antigen uptake and presentation (red ), dendritic cell subsets can prioritize different
innate receptors for signaling, especially Toll-like receptors (blue). Langerhans cells (not shown) are likely to be a distinct additional
subset. Comparable groups of dendritic cells are found in humans, but many of the actively used markers are different from the mouse.
cells are also processed, as shown by Marion
Subklewe and Christian Munz for Epstein
Barr virus latency gene products (100) and by
Palucka, Banchereau, and their team in Dallas
studying several melanoma antigens (101). For
me, a particular unknown is the handling of self
and environmental antigens within dying cells
to maintain peripheral tolerance. I am struck
by the evidence from Gordon MacPherson in
Oxford that dendritic cells are always carrying
intestinal epithelial cell contents via lymphatics
and on to the dendritic cells in the T cell
area of the mesenteric lymph node (102).
This seems like an efficient way to display the
“harmless” to the immune system and bring
about peripheral tolerance. Special subsets of
dendritic cells may be involved.
Because of distinctions in innate receptors
(Figure 2), one could surmise that each
subset is designed to bring about rapid innate
responses to the wide range of self and nonself
components with which the immune system
must deal. This was proposed early on by
Yong-Jun Liu, who discovered that plasmacy-
toid dendritic cells were unique in being able
to make large amounts of type I interferon
in response to nonreplicating viruses (103).
The raison d’être for the different dendritic
cell subsets is receiving considerable attention
because a more complete picture is needed,
as summarized by two of the leaders in the
field, William Heath and Frank Carbone in
Melbourne (104). I suspect that the in vivo
targeting of antigens within monoclonal
antibodies to dendritic cell lectins will help
decipher the function of dendritic cell subsets
in intact animals and humans. Better genetic
tools are being developed to deplete dendritic
cells and their subsets (as reviewed in 105), but
targeting allows one to assess and direct the im-




Many diseases that involve the immune sys-
tem often interfere with dendritic cell func-
tion, as occurs with microbial pathogens and
tumors. Alternatively, the disease exploits den-
dritic cells, as occurs in allergy, autoimmu-
nity, and transplantation (reviewed in 106). Paul
Cameron and Melissa Pope, now Robbiani,
studied HIV-1 in tissue culture and found that
dendritic cells serve as a conduit to ferry virus
to its major site for replication, T cells (107,
108). But the reciprocal to pathogenesis is also















































































IY30CH01-Steinman ARI 17 February 2012 10:54
to prevent and combat disease. This is especially
the case for vaccination.
Vaccination is the route to so many medi-
cal success stories, and it depends upon the in-
duction of antigen-specific, protective immune
memory. Current vaccines largely prevent in-
fection but not the other types of disease de-
picted in Figure 1, and they work primarily by
inducing protective antibodies. Medicine now
needs to discover T cell–based vaccines that en-
hance resistance to cancer and to infectious dis-
eases such as AIDS and tuberculosis. Conceiv-
ably, antigen-specific Tregs can also be induced
to suppress unwanted immune reactions, some-
thing we are intrigued by because of Uri Sela’s
findings. He showed not only that dendritic
cells are special inducers of Foxp3+ Tregs, but
also that the latter can persist for months in vivo
during the suppression of inflammatory graft-
versus-host disease (109). A challenge now is to
learn how to expand disease-suppressive Tregs
in vivo.
We decided to enter the vast realm of vac-
cines twice. The first time in the 1990s stemmed
from discoveries showing that antigen-loaded
dendritic cells could immunize mice and, later,
healthy volunteers. Initial research in can-
cer patients was led by Gerold and Beatrice
Schuler in Erlangen (110) and Palucka, Faye,
and Banchereau in Dallas (111). Other inves-
tigators, beginning with Ron Levy and Ed
Engleman at Stanford with lymphoma (112),
also reported that ex vivo antigen-loaded den-
dritic cells could immunize patients with can-
cer antigens (reviewed in 113, 114). However,
the measured immune responses seem weak and
have yet to be linked with prolonged survival.
The newly licensed Dendreon Corporation’s
Provenge vaccine for advanced prostate cancer
might be based on dendritic cell immunization
to a nonmutated prostate self antigen (115), but
this remains unclear.
The big obstacle to research with ex vivo–
derived dendritic cells is organizational: How
do we optimize two-arm studies of the many
variables that lead to the induction of durable
and broad anticancer immunity, and how do we
gain financial support for immunotherapy? It is
often written that ex vivo dendritic cell ther-
apy is complicated from a procedural point of
view. I completely disagree. The technology has
advanced to the stage where machines handle
the monocyte-enriched fraction derived from a
leukapheresis and differentiate the monocytes
into dendritic cells in very large numbers. If a
single leukapheresis could lead to the prepara-
tion of several dozen effective, nontoxic vacci-
nations with a broad spectrum of tumor anti-
gens, it seems unwarranted to stifle the field
as being too complicated. Granted, the scien-
tific obstacles are substantial, as reviewed by
Kees Melief and Carl Figdor from Leiden and
Nijmegen (116, 117), but research needs to take
place with proper support and organization.
This is true for the entire field of cancer im-
munology in people. It remains a major mys-
tery why immune approaches to cancer are so
underemphasized relative to other modalities,
which immune therapies should also be able to
complement, as reviewed by Laurence Zitvogel
and Guido Kroemer from Paris (118).
The second time we decided to enter
the vaccine realm, and where we remain
active, stemmed from the above discoveries
of antigen-specific uptake receptors as means
to allow dendritic cells, or subsets of them, to
capture vaccine antigens efficiently. Prior to
the identification of DEC-205, beginning with
Mary Crowley’s work, relatively large doses of
antigen, 100 μg or more, were being injected
in vivo (119). But once foreign proteins were
introduced into anti-DEC-205 monoclonal
antibodies, Daniel Hawiger, Laura Bonifaz,
and Christine Trumpfheller found that the
antigens became highly immunogenic in low
doses (86, 120–122). Enhanced immunization
specifically required DEC-205. Binding of the
fusion monoclonal antibody to Fc receptors was
minimized by mutations introduced by long-
standing colleague Jeffrey Ravetch, and the
observed increase in immunity using anti-DEC
fusion monoclonal antibody was abolished in
DEC knockout mice. Interestingly, the intro-
duction of proteins into a monoclonal antibody
is in many cases an excellent way to manu-
facture defined antigens for vaccines. More
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importantly, one has an opportunity to direct
and harness dendritic cell science with the
targeting antibody.
So far, approximately 1 μg of antibody fu-
sion protein leads to sizeable CD4+ T cell re-
sponses in mice, and cross-priming of CD8+
T cells is also evident. Leonia Bozzacco made
an important finding on cross-presentation, i.e.,
it is possible to achieve cross-presentation to
CD8+ T cells with DEC-205-targeted HIV
gag protein in many MHC haplotypes (123);
this breadth of cross-presentation will be essen-
tial for vaccination. Likewise, for cancer pro-
teins, where we focus on nonmutated but hy-
perexpressed cancer antigens such as HER2 and
mesothelin, Bei Wang finds that DEC-205 tar-
geting makes it feasible for small amounts of
proteins to elicit immunity, including CD8+
T cell immunity or cross-priming (124; B.
Wang, N. Zaidi, L.Z. He, K. Zhang, J.M.Y.
Kuroiwa, T. Keler, R.M. Steinman, submitted
manuscript). Our emphasis is on “one-for-all”
vaccines for broad groups of cancer patients,
with the goal to start the immune response ef-
fectively. Then the patient’s dendritic cells, if
maturing during the local killing of tumor cells,
will have a chance to take over, present dying
tumor cells, and spread the immune response to
the plethora of mutant proteins in solid tumors.
The biggest decision currently is selecting
the stimulus that needs to be delivered to bring
about appropriate dendritic maturation for
strong helper and killer T cell immunity. In the
case of vaccines to resist cancer and infection,
the dendritic cells need to be steered away
from their steady-state tolerogenic functions,
e.g., by a stimulus that can mimic the innate
signaling that takes place during an infection.
This research was given a huge boost with
the definition of a new spectrum of clinically
feasible innate stimuli, i.e., synthetic agonists
for families of microbial recognition receptors,
first by Shizuo Akira and colleagues in Osaka
(125). This synthetic microbial agonist field
means that one chemical compound should in
principle mimic the action of a whole class of
microbes, e.g., RNA viruses and gram-negative
bacteria.
As a result of experiments with a consortium
of investigators in Germany, including Klaus
Uberla, Paul and Klara Racz, Christiane
Stahl Hennig, and Ralf Ignatius, synthetic
double-stranded RNA (poly IC) appeared to
be promising adjuvant (126). Considerable
research in mice by Paula Longhi came to the
same conclusion and established that poly IC
gained its potency as an adjuvant by being a
strong inducer of innate interferon production
(127). Marina Caskey and Sarah Schlesinger
took these findings into the clinic to address
some important questions together with Rafick
Sékaly and colleagues in Port St. Lucie. They
have found that these synthetic compounds
can reliably stimulate a broad innate immune
response in people and that the compounds
really are microbial mimics, reproducing to
a considerable extent the innate response of
people receiving the successful live attenuated
yellow fever vaccine (128).
Research with a new synthetic TLR4 ago-
nist, glucosyl pyranosyl lipid A (GLA), is also
underway by Longhi together with Steve Reed
from Seattle (129). Different classes of adju-
vants might be needed to tailor the immune
response to the particular pathogen and to op-
timize protective immunity. A good model for
protection induced by dendritic cell–targeted
protein vaccines is the ongoing PhD thesis work
of Ines Matos. She is using a protozoan parasite
protein to show the value of dendritic cell tar-
geting for inducing protection against a human
pathogen, Leishmania major, that infects mice,
like humans, through the skin.
The need for new vaccines based on T
cell immunity is driving dendritic cell biology
in an exciting way because it allows scientists
to focus on directing the antigen-specific im-
mune response in intact animals and people,
including patients with cancer (117, 130). The
goal is to select and guide those rare clones in
Burnet’s repertoire so that the clones provide
the appropriate response. Transgenic T cells
can provide excellent tools in this research, but
we encounter instances in which the responses
of transgenic T cells do not represent what one
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are four examples of recent findings focused
on understanding dendritic cells in the real-life
context of vaccination with defined proteins and
adjuvants:
1. Developing a vaccine from basic princi-
ples requires that one understand how in-
nate immunity and adaptive immunity are
linked in vivo. Most cells make responses
to innate stimuli, but dendritic cells need
to be engaged to gain control of adaptive
immunity. Impressively, within only 4 h
of administering an adjuvant like poly IC
or GLA, the antigen-capturing dendritic
cells have become immunogenic, able to
directly immunize the T cells of a naive
animal (127, 129).
2. Dendritic cells have many different re-
ceptors capable of bringing about anti-
gen presentation. To date, Juliana Idoy-
aga and Christine Trumpfheller find that
different receptors on the same CD8αα
dendritic cell subset in mice mediate sim-
ilar T cell priming when targeted with
antigen (131).
3. In a collaboration to study antigen target-
ing in nonhuman primates with Robert
Seder at NIH, we found surprisingly that
priming with a dendritic cell–targeted
protein vaccine allowed the animals to
make an unusually large CD8+ T cell
response to a boost with a replication-
defective recombinant NYVAC vector
(132). The NYVAC vector from Gepi
Pantaleo and Mariano Esteban was it-
self not detectably immunogenic, even
with two doses. Yet the CD8+ T cell re-
sponse to NYVAC was vigorous when
the primate immune system had been
primed with a clinical grade protein vac-
cine that targeted HIV gag to human
DEC-205.
4. Scott Barbuto, a current PhD student in
the laboratory, decided to learn to target
both the antigen and innate stimulus se-
lectively to dendritic cells. He is proving
that dendritic cells alone are sufficient for
initiating immunity.
Our vaccine research is being extended
by physician scientists Marina Caskey, Bryan
Yipp, and Niroshana Anandasabapathy to stud-
ies in healthy volunteers. The program is be-
ing directed by our clinical director, Sarah
Schlesinger, with enormous help from Sarah
Pollak and Lauren Sinnenberg. Our first proof-
of-concept study uses HIV gag p24 as the
antigen targeted within human anti-human
DEC-205 monoclonal antibody; the latter is
manufactured through an active collaboration
with Tibor Keler at Celldex Therapeutics
(133). The first adjuvant being tested is poly IC.
In addition to adjuvant choice, our HIV protein
vaccine research has to address some additional
key gaps, such as the inclusion of HIV envelope
to elicit antibody responses and the induction
of immunity at mucosal surfaces.
While it is exciting to be able to pursue
this research, our experience is dramatizing the
powerful obstacles to obtaining financial sup-
port to learn to direct the immune system in
people. Fortunately, I have had a tremendous
boost from The Rockefeller University and its
research hospital, the first center for research
on human subjects in the United States, and
also from New York City, where bright minds
abound and the community takes on consider-
able responsibility in its support for research.
DECIDING TO STAY ON THE
PATH OF VACCINE SCIENCE
IN PRECLINICAL MODELS AND
IN HUMAN SUBJECTS
It has been an amazing privilege to watch the
progress of immunology from the early days
of clonal selection and cell-mediated immunity
to the present. This progress may seem over-
whelming for investigators who are now begin-
ning in the field, when they encounter hundreds
of molecules with their CD numbers (in con-
trast there were only two markers when I began,
thy-1 or theta for T cells and surface Ig for B
cells), and dozens of cytokines, chemokines, cell
types, signal transducers, and transcription fac-
tors. On the other hand, young scientists, the
key to our future, can easily understand that
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all the progress makes it easier to address the
search for better prevention and treatment of
conditions influenced by the immune system
(Figure 1). The existence of these conditions
says loudly and clearly that there are huge dis-
coveries yet to be made to move forward. Our
laboratory is committed to vaccines as a driving
force for future discoveries.
The complexity of adaptive immunity is
humbling, but at the same time it is stimulating
to be part of a profession that is making great
progress, particularly with the introduction
of several new pharmaceuticals, mainly anti-
bodies. My initial decision was to learn how
antigen-specific immunity is initiated. It is
exciting to see how dendritic cells are providing
routes to the control of antigen-specific T cell
immunity in its different helper, killer, and
regulatory forms. In humans, this will form the
basis for a myriad of future medical advances
to deal with the conditions listed in Figure 1.
It was exciting when dendritic cells appeared
first as novel cells, and it remains exciting that
these cells represent a novel force in medicine.
EDITOR’S NOTE
During the last four and one-half years of his life, Ralph Steinman lived with pancreatic cancer.
Tragically, he succumbed to the disease just two and one-half days before receiving the Nobel
Prize for Physiology or Medicine and just three weeks after submitting this manuscript.
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